Skip to main content

Advertisement

Springer Nature Link
Log in

Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer

  • Original Article
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Targeted oncolytic adenoviruses capable of replication selectively in cancer cells are an appealing approach for the treatment of various cancer types refractory to conventional therapies. The aim of this study was to evaluate the effect of Ad5/3MDR1E1, a multidrug resistance gene 1 (MDR1)-targeted fiber-modified replication-competent adenovirus for the therapy of platinum-pretreated ovarian cancer in combination with cytostatic agents.

Methods

MDR1-specific tumor cell killing of Ad5/3MDR1E1 was systematically evaluated in chemotherapy naïve and pretreated ovarian cancer cells in vitro. Combinations of Ad5/3MDR1E1 and cytostatic agents were studied in vivo and in vitro. An in vivo hepatotoxicity model was used to evaluate liver toxicity.

Results

We demonstrate efficient oncolysis of Ad5/3MDR1E1 in chemotherapy-resistant ovarian cancer cells as well as therapeutic efficacy in an orthotopic mouse model. Further, combining Ad5/3MDR1E1 with paclitaxel resulted in greater therapeutic benefit than either agent alone.

Conclusion

These preclinical data suggest that a fiber-modified adenovirus vector under the control of the MDR1 promoter represents a promising treatment strategy for platinum-pretreated ovarian cancer as a single agent or in combination with conventional anticancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS, Gottesman MM (2004) Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66(6):1397–1405

    Article  PubMed  CAS  Google Scholar 

  • Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behaviour of human epithelial ovarian cancer. Cancer Res 65(8):3025–3029. doi:10.1158/0008-5472.CAN-04-3931

    PubMed  CAS  Google Scholar 

  • Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A (2002) Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 62(5):1266–1270

    PubMed  CAS  Google Scholar 

  • Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  PubMed  CAS  Google Scholar 

  • Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M (2004) Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 64(12):4319–4327

    Article  PubMed  CAS  Google Scholar 

  • Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72(12):9706–9713

    PubMed  CAS  Google Scholar 

  • Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT (2001) Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61(3):813–817

    PubMed  CAS  Google Scholar 

  • Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J (2006) Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556–562. doi:10.1158/1078-0432.CCR-05-1892

    Article  PubMed  CAS  Google Scholar 

  • Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9(2):555–561

    PubMed  CAS  Google Scholar 

  • Hoffmann D, Bangen JM, Bayer W, Wildner O (2006) Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther 13(21):1534–1544. doi:10.1038/sj.gt.3302806

    Article  PubMed  CAS  Google Scholar 

  • Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9(6):1211–1218

    Article  PubMed  CAS  Google Scholar 

  • Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10(5):967–972. doi:10.1016/j.ymthe.2004.08.002

    Article  PubMed  CAS  Google Scholar 

  • Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29(45):6051–6063. doi:10.1038/onc.2010.335

    Google Scholar 

  • Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL (2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F–1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63(7):1490–1499

    PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60 (5):277–300. doi:10.3322/caac.20073

  • Jessen BA, Mullins JS, De Peyster A, Stevens GJ (2003) Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol Sci 75(1):208–222

    Article  PubMed  CAS  Google Scholar 

  • Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT (2002a) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8(1):275–280

    PubMed  CAS  Google Scholar 

  • Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A (2002b) Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 5(6):695–704

    Article  PubMed  CAS  Google Scholar 

  • Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A (2003) Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8(3):449–458

    Article  PubMed  CAS  Google Scholar 

  • Kanerva A, Raki M, Hemminki A (2007) Gene therapy of gynaecological diseases. Expert Opin Biol Ther 7(9):1347–1361. doi:10.1517/14712598.7.9.1347

    Article  PubMed  CAS  Google Scholar 

  • Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26(16):2616–2618. doi:10.1200/JCO.2008.16.2123

    Article  PubMed  Google Scholar 

  • Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, Hung MC (2003) Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res 63(19):6229–6236

    PubMed  CAS  Google Scholar 

  • Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z (2004) Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 10(24):3634–3638

    PubMed  CAS  Google Scholar 

  • Lu S, Wang X, Xiao L, Cai L, Zhang Y, Wang H, Wang Z (2007) Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. Cancer Biol Ther 6(3):397–404

    Article  PubMed  CAS  Google Scholar 

  • Mantwill K, Kohler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B, Holm PS (2006) Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 66(14):7195–7202. doi:10.1158/0008-5472.CAN-05-2339

    Article  PubMed  CAS  Google Scholar 

  • Nelson AR, Davydova J, Curiel DT, Yamamoto M (2009) Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 100(11):2181–2187. doi:10.1111/j.1349-7006.2009.01289.x

    Article  PubMed  CAS  Google Scholar 

  • Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9(12):1769–1774

    Article  PubMed  CAS  Google Scholar 

  • Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A (2005) Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12(15):1198–1205. doi:10.1038/sj.gt.3302517

    Article  PubMed  CAS  Google Scholar 

  • Raki M, Rein DT, Kanerva A, Hemminki A (2006) Gene transfer approaches for gynecological diseases. Mol Ther 14(2):154–163. doi:10.1016/j.ymthe.2006.02.019

    Article  PubMed  CAS  Google Scholar 

  • Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A, Kanerva A (2008) Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 108(1):166–172. doi:10.1016/j.ygyno.2007.09.013

    Article  PubMed  CAS  Google Scholar 

  • Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus-based cancer gene therapy. Future Oncol 2(1):137–143. doi:10.2217/14796694.2.1.137

    Article  PubMed  CAS  Google Scholar 

  • Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A, Hess AP, Maass N, Baldus SE, Bauerschmitz G, Breidenbach M (2011) Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol Oncol 123(1):138–146. doi:10.1016/j.ygyno.2011.06.007

    Google Scholar 

  • Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234. doi:10.1038/nrd1984

    Article  PubMed  CAS  Google Scholar 

  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103(30):11154–11159. doi:10.1073/pnas.0603672103

    Article  PubMed  CAS  Google Scholar 

  • Vanderkwaak TJ, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT (1999) An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 74(2):227–234

    Article  PubMed  CAS  Google Scholar 

  • Wrighton SA, Ring BJ, VandenBranden M (1995) The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 23(2):199–208

    Article  PubMed  CAS  Google Scholar 

  • Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X (2004a) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23(12):1666–1670. doi:1000467X2004121666

    PubMed  Google Scholar 

  • Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X (2004b) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23(12):1666–1670. doi:1000467X2004121666

    PubMed  Google Scholar 

  • Yadav S, van Vlerken LE, Little SR, Amiji MM (2009) Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63(4):711–722. doi:10.1007/s00280-008-0790-y

    Article  PubMed  CAS  Google Scholar 

  • Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT (2003) Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125(4):1203–1218

    Article  PubMed  CAS  Google Scholar 

  • You L, Yang CT, Jablons DM (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60(4):1009–1013

    PubMed  CAS  Google Scholar 

  • Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR (2001) Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61(2):517–525

    PubMed  CAS  Google Scholar 

  • Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3(1):1–19

    Article  PubMed  CAS  Google Scholar 

  • Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M, Widschwendter M, Bergelson JM, Marth C (2002) Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 9(16):1093–1100

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Düsseldorf Medical Center, Moorenstrasse 5, 40225, Düsseldorf, Germany

    Daniel T. Rein, Anne Volkmer, Gerd Bauerschmitz, Ines M. Beyer, Wolfgang Janni, Markus C. Fleisch & Anne Kathrin Welter

  2. Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA, USA

    Ines M. Beyer

  3. Department of Obstetrics and Gynecology, Rhine-Westphalian Technical University, Aachen, Germany

    Dirk Bauerschlag & Martina Breidenbach

  4. Institute for Clinical Research and Development, Mainz, Germany

    Thomas Schöndorf

Authors
  1. Daniel T. Rein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Volkmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerd Bauerschmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ines M. Beyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus C. Fleisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anne Kathrin Welter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dirk Bauerschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas Schöndorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Martina Breidenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel T. Rein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rein, D.T., Volkmer, A., Bauerschmitz, G. et al. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J Cancer Res Clin Oncol 138, 603–610 (2012). https://doi.org/10.1007/s00432-011-1135-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-011-1135-5

Keywords

Search

Navigation